Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BIOFOSTE

Financiado

Cerrado

Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis BIOFOSTE

OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years. The clinical manifestations of OA are pain and functional dis... ver más

30/09/2016

IRTAL-LPMRI-SRL

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ISTITUTO DI RICERCA TRASLAZIONALE PER LAPPARA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-09-30

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

IRTAL-LPMRI-SRL

50.00K€ | Lider

CYANAGEN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LIVELMIA Innovative assay for microRNAs analysis 71K€ Cerrado

PID2021-126469OB-C21 HYBRID REPRESENTATIONS OF OA: FROM BIOLOGY TO PATIENT CHARAC... 156K€ Cerrado

D-BOARD Novel Diagnostics and Biomarkers for Early Identification of... 8M€ Cerrado

OACTIVE Advanced personalised multi scale computer models preventin... 5M€ Cerrado

FRAILOMIC Utility of omic based biomarkers in characterizing older ind... 15M€ Cerrado

MUOTO Commercialization of 3D histopathological evaluation of oste... 150K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2016-03-03
Fecha Fin: 2016-09-30

Líder del proyecto

ISTITUTO DI RICERCA TRASLAZIONALE PER LAPPARA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years. The clinical manifestations of OA are pain and functional disability that can limit the normal activities of daily life and lead to depression and isolation. OA assessment is mainly carried out using radiography, which is the gold standard for diagnostic purposes. However this approach has poor sensitivity and diagnosis is obtained only when the articular cartilage has degraded significantly. Based on the extremely high economic burden, quantified in tens of billions of euro in the world, which will tend to increase in the future years, there is a need to validate OA biomarkers. In fact, although several proteins and miRNAs have been described as being altered and correlated with OA progression, there are no currently available BIOmarkers for OA diagnosis. This project concerns the development and clinical validation of a combined panel composed of proteins and miRNAs, which have been found altered in OA patients, combined with a new marker identified by IRTAL and a patented secondary chemiluminescence ELISA enhancer developed by CYANAGEN to ensure a high sensitivity for an early OA diagnosis. Our final goal is to validate and commercialize an IVD kit that may help the clinicians make an early diagnosis or predict the outcome/prognosis of OA patients, to improve the patients' quality of daily life while decreasing the related economic losses due to unproductivity, absenteeism, disability and also in terms of surgical procedures and hospitalization resources for the Health care systems. This project will allow involved SMEs to enter in the IVD market seizing the related business opportunity. In Phase 1 of the project we will select the optimal biomarkers, determine the market and clinical utility of the diagnostic test

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores